» Articles » PMID: 32867508

Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome: Insights From the SWEDEHEART Registry

Overview
Journal Circulation
Date 2020 Sep 2
PMID 32867508
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The comparative efficacy and safety of ticagrelor versus clopidogrel in older patients with myocardial infarction (MI) has received limited study.

Methods: We performed an observational analysis of all patients ≥80 years (n=14 005) who were discharged alive with aspirin combined with either clopidogrel (60.2%) or ticagrelor (39.8%) after a MI between 2010 and 2017 registered in the national registry SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). Inverse probability treatment weighting was used in Cox regression models to adjust for differences in demographics, in-hospital therapies, and medications. The primary ischemic outcome (death, MI, or stroke), and bleeding were obtained from national registries at 1 year. A sensitivity analysis in <80-year-old patients was performed.

Results: In patients ≥80 years, the incidence of the primary ischemic outcome (hazard ratio [HR], 0.97 [95% CI, 0.88-1.06]) was similar for ticagrelor- and clopidogrel-treated patients. Ticagrelor was associated with a 17% and 48% higher risk of death (HR, 1.17 [95% CI, 1.03-1.32]) and bleeding (HR, 1.48 [95% CI, 1.25-1.76]), but a lower risk of MI (HR, 0.80 [95% CI, 0.70-0.92]) and stroke (HR, 0.72 [95% CI, 0.56-0.93]). In <80-year-old patients, the incidence of the primary ischemic outcome was 17% (HR, 0.83 [95% CI, 0.77-0.89]) lower with ticagrelor. Ticagrelor was associated with 15% (HR, 0.85 [95% CI, 0.76-0.96]) lower risk of death, 32% higher risk of bleeding (HR, 1.32 [95% CI, 1.18-1.47]), but lower risk of MI (HR, 0.82 [95% CI, 0.75-0.91]) and stroke (HR, 0.82 [95% CI, 0.69-0.98]).

Conclusions: Ticagrelor use among elderly patients with MI was associated with higher risk of bleeding and death compared with clopidogrel. A randomized study of ticagrelor versus clopidogrel in the elderly is needed.

Citing Articles

Management of Acute Coronary Syndromes in Older People: Comprehensive Review and Multidisciplinary Practice-Based Recommendations.

Narendren A, Whitehead N, Burrell L, Yudi M, Yeoh J, Jones N J Clin Med. 2024; 13(15).

PMID: 39124683 PMC: 11312870. DOI: 10.3390/jcm13154416.


Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope.

Jones D, Nicolas J, Beerkens F, Satish M, Feldman D, Cao D Rev Cardiovasc Med. 2024; 23(6):207.

PMID: 39077183 PMC: 11273875. DOI: 10.31083/j.rcm2306207.


Invasive Strategy in Octogenarians with Non-ST-Segment Elevation Acute Myocardial Infarction.

Alvarez-Zaballos S, Juarez-Fernandez M, Martinez-Selles M Rev Cardiovasc Med. 2024; 25(3):78.

PMID: 39076933 PMC: 11263832. DOI: 10.31083/j.rcm2503078.


Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Fioretti V, Sperandeo L, Gerardi D, Di Fazio A, Stabile E J Clin Med. 2024; 13(14).

PMID: 39064269 PMC: 11277659. DOI: 10.3390/jcm13144229.


Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery.

Jiang Q, Huang K, Han L, Kong H, Yang Z, Hu S Clin Transl Sci. 2024; 17(6):e13862.

PMID: 38877696 PMC: 11178516. DOI: 10.1111/cts.13862.